Symbiotec Pharmalab IPO
- 2 hours ago
- 2 min read
About the Company: Symbiotec Pharmalab is a pharmaceutical and biotechnology company engaged in manufacturing steroidal APIs, nutritional ingredients, CDMO solutions, and complex injectable products.
The company has integrated capabilities across organic chemistry, biotechnology, fermentation, research and development, and manufacturing. Its business is supported by backward integration, large-scale fermentation capacity, and multiple manufacturing facilities, serving customers across domestic and global markets.
IPO Objectives:
Repayment or prepayment of borrowings
General corporate purposes
Symbiotec Pharmalab IPO: Key Details
IPO Date: 24–27 Aug 2026
Price Band: ₹938–₹988 per share
Lot Size: 15 shares
IPO Size: ₹1,757 Cr
Fresh Issue: ₹150 Cr
OFS: ₹1,607 Cr
GMP: +33% (For information only)
Financial Snapshot:
FY24: Revenue ₹716 Cr | Profit ₹100 Cr | Debt ₹247 Cr
FY25: Revenue ₹752 Cr | Profit ₹96.79 Cr | Debt ₹541 Cr
FY26: Revenue ₹850 Cr | Profit ₹110 Cr | Debt ₹388 Cr
The company has shown overall growth in revenue and profitability, while debt reduced to ₹388 Cr in FY26 from ₹541 Cr in FY25.
Valuation Snapshot:
At the upper price band of ₹988 per share:
Market Capitalisation: ₹6,348 Cr
P/E Ratio: 57.6x | Sector P/E: 19.33x
P/B Ratio: 5.52x | Sector P/B: 2.74x
DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matters published here are purely for educational and information purposes only and under no circumstances should be used for making investment decisions. Readers must consult a qualified financial advisor before making any actual investment decisions, based on the information published here. Any reader making decisions based on any information published here does so entirely at their own risk. Investors should bear in mind that any investment in the stock market is subject to unpredictable market-related risks. The author has no plans to invest in this offer, and also the author does not recommend investing in any offer published on this website.
Comments